Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $118.15M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 9.92M
Average 2.73M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
Intrinsic Alpha fair value
Locked
Current Price
$1.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -81.5% | +467.8% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -81.5% over three years. Forward estimates point to Revenue at +467.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Opus Genetics, Inc. NASDAQ:IRD | $347.76M | $4.18 | Not rated | -33.0 | +111.40% |
Agenus Inc. NASDAQ:AGEN | $322.91M | $7.15 | Not rated | 1.7 | +43.12% |
Alector, Inc. NASDAQ:ALEC | $255.69M | $2.29 | Not rated | -1.4 | +91.67% |
Fate Therapeutics, Inc. NASDAQ:FATE | $213.89M | $1.84 | Not rated | -1.8 | +1.00% |
Seer, Inc. NASDAQ:SEER | $90.26M | $1.63 | Not rated | -1.4 | -28.61% |
Spero Therapeutics, Inc. NASDAQ:SPRO | $59.98M | $1.03 | Undervalued | 8.2 | -61.33% |
Seres Therapeutics, Inc. NASDAQ:MCRB | $19.68M | $1.98 | Overvalued | -1.3 | -75.67% |
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | $16.17M | $0.22 | Not rated | -1.3 | +46.79% |
Actuate Therapeutics Inc NASDAQ:ACTU | $7.90M | $0.33 | Not rated | -2.3 | -65.68% |
Continue the stock analysis
Jump to another research area for this company.